🧾 What This Document Is

This is AgomAb Therapeutics' 20-F Annual Report, a comprehensive filing required by the U.S. Securities and Exchange Commission (SEC) for foreign companies like this Belgian biotech. Think of it as the company's official annual "check-up" for U.S. investors, covering everything from business strategy and financial health to its biggest risks.

👉 Why it matters: It's the most detailed, audited snapshot you'll get of the company's operations, finances, and future plans.

🏢 What The Company Does

In simple terms, AgomAb is a clinical-stage biopharmaceutical company. They don't sell any drugs yet. Instead, they discover and develop new antibody therapies (called "AgomAbs") to treat serious fibrotic diseases—conditions where organs become scarred and stiff, like in the lungs, liver, or heart.

👉 Their niche: They aim to create "disease-modifying" treatments, not just ones that manage symptoms. Their lead candidate, AGMB-445, is being developed for idiopathic pulmonary fibrosis (IPF), a severe lung disease.

💰 Financial Highlights & Position

As a research-focused biotech, the numbers tell a story of heavy investment before any revenue.

• Cash is King: As of December 31, 2025, they held €64.8 million in cash and equivalents. This is their fuel to keep operating.
• Burning Cash for R&D: For the year, they reported a net loss of €31.5 million. The vast majority of this loss stems from research and development (R&D) expenses, which were €23.8 million. This is typical for a company funding clinical trials.
• Assets are mostly Intellectual Property: Their total assets are €86.4 million. A significant portion is tied up in intangible assets (€53.3 million), primarily the value of their drug licenses and "in-process R&D."
• Funding Comes from Investors, Not Sales: They have no product revenue. Their total equity is €80.2 million, built entirely through share issuances (selling ownership) to investors. They have €3.2 million in contingent consideration (potential future payments related to a past acquisition).

🧪 Pipeline & Clinical Trials

This is the heart of their business. Their success depends entirely on whether their drugs work.

• Lead Candidate: AGMB-445 for IPF. This is their most advanced program. The report details the ongoing Phase 1b clinical trial, which is testing the drug's safety and how it moves through the body in patients.
• Other Programs: They have earlier-stage candidates, including AGMB-129 for a liver condition and others targeting other fibrotic diseases. Much of their R&D spend is focused on moving these through preclinical testing.

👉 Why it matters: Clinical trials are expensive, risky, and slow. Each phase (1, 2, 3) must show safety and effectiveness to get regulatory approval. Failure at any stage can wipe out value.

⚠️ Key Risk Factors

The filing dedicates many pages to what could go wrong. Here are the most critical themes:

1. Need More Money: They expect to continue operating at a loss and will need to raise significant additional funding to complete clinical trials and commercialize drugs. If they can't, they may have to delay or cancel programs.
2. Pipeline Risk is Existential: Their lead and future drug candidates could fail in clinical trials due to safety or efficacy issues. Since they have no marketed products, a major failure could severely harm the company.
3. No Commercial Experience: They have never launched or sold a drug. Building a commercial team and navigating the market is a huge, unproven challenge.
4. Competition & IP: The field for fibrosis treatments is competitive. They must protect their patents and trade secrets, and their technology may be rendered obsolete by competitors.

👥 Governance & Share Structure

• Foreign Private Issuer: As a Belgian company, they follow certain Belgian corporate governance rules instead of all U.S. rules. This can mean less frequent financial reporting and different shareholder rights.
• Concentrated Ownership: A small group of executives, directors, and major investors holds significant sway. This can make it harder for smaller investors to influence decisions.
• Dual-Class Share Structure: Their American Depositary Shares (ADS), which trade on Nasdaq (ticker: AGMB), each represent one common share. However, the underlying common shares are not separately listed on any exchange, which can limit liquidity if you try to hold the actual shares.

🌍 Industry Context

AgomAb operates in the high-risk, high-reward world of biotech innovation. The market for treating fibrotic diseases is significant because current treatments are often limited to managing symptoms, not stopping disease progression. Success in this field can lead to blockbuster drugs, but the path is littered with failures.

📈 What This Signals

This report signals a company in heavy investment mode. The focus is entirely on clinical execution and preserving cash for future R&D. The lack of revenue means the stock's value is almost entirely based on speculation about the future success of its drug pipeline.

🔮 What's Next

• Clinical Milestones: The key upcoming events are data readouts from their AGMB-445 Phase 1b trial and decisions on advancing to later-phase trials.
• Fundraising: Investors should expect the company to tap capital markets again (by issuing more shares) to fund operations beyond 2026.
• Partnerships: They may seek collaboration or licensing deals with larger pharma companies to help fund development and commercialization.

🧠 The Analogy

AgomAb is like a team of master watchmakers trying to invent a revolutionary new clock. They have a promising blueprint (their antibody platform) and have built a complex, promising prototype (AGMB-445). Right now, they are in a workshop, funded by backers, meticulously testing the prototype's every gear and spring. They are not selling clocks yet; they are focused entirely on proving their invention works perfectly. The backers' patience and money will run out if they can't show a working clock soon.

🧩 Final Takeaway

AgomAb is a pure-play R&D biotech with promising science but a long, costly, and risky road ahead. Its future is binary: it will likely be worth a lot more if its lead drug succeeds in clinical trials, or significantly less if it fails. Investors are betting on the science, not on current financials.